Iranian Journal of Diabetes and Obesity
Shahid Sadoughi University Of Medical Sciences
Tue, Jun 3, 2025
[Archive]
Volume 17, Issue 2 (5-2025)
IJDO 2025, 17(2): 130-140 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Addissouky T A. Orchestrating Metabolic Homeostasis: The Role of Gut Hormones in Next-Generation Therapies for Metabolic Syndrome. IJDO 2025; 17 (2) :130-140
URL: http://ijdo.ssu.ac.ir/article-1-955-en.html
URL: http://ijdo.ssu.ac.ir/article-1-955-en.html
Department of Biochemistry, Science Faculty, AL-Mustaqbal University, 51001, Hillah, Babylon, Iraq. New burg El-Arab Hospital, Ministry of Health, Alexandria, Egypt. Department of Chemistry, Science Faculty, Menoufia University, Menoufia, Egypt. American Society for Clinical Pathology (ASCP), Chicago, USA.
Abstract: (35 Views)
Metabolic disorders, including obesity and type 2 diabetes, have reached epidemic proportions globally, necessitating novel therapeutic approaches. The gut-brain axis, particularly gut hormones, plays a crucial role in metabolic regulation, offering promising targets for intervention.
This review aims to synthesize current knowledge on gut hormone-based therapies for metabolic disorders, focusing on their mechanisms of action and therapeutic potential.
Gut hormones, including GLP-1, GIP, PYY, ghrelin, and oxyntomodulin, orchestrate complex physiological responses to nutrient intake, influencing insulin secretion, appetite, and energy expenditure. Recent advancements in incretin-based therapies, particularly GLP-1 receptor agonists and dual GLP-1/GIP agonists, have shown remarkable efficacy in improving glycemic control and promoting weight loss. These therapies exploit the synergistic actions of multiple gut hormones, offering a more comprehensive approach to metabolic regulation. Emerging research on PYY analogs and ghrelin antagonists further expands the therapeutic landscape. However, challenges remain in optimizing delivery methods, ensuring long-term efficacy, and mitigating potential side effects.
Gut hormone-based therapies represent a paradigm shift in the management of metabolic disorders. By harnessing the intricate signaling networks of the gut-brain axis, these innovative approaches offer the potential for more effective and targeted interventions in obesity and type 2 diabetes, paving the way for personalized treatment strategies in metabolic medicine.
This review aims to synthesize current knowledge on gut hormone-based therapies for metabolic disorders, focusing on their mechanisms of action and therapeutic potential.
Gut hormones, including GLP-1, GIP, PYY, ghrelin, and oxyntomodulin, orchestrate complex physiological responses to nutrient intake, influencing insulin secretion, appetite, and energy expenditure. Recent advancements in incretin-based therapies, particularly GLP-1 receptor agonists and dual GLP-1/GIP agonists, have shown remarkable efficacy in improving glycemic control and promoting weight loss. These therapies exploit the synergistic actions of multiple gut hormones, offering a more comprehensive approach to metabolic regulation. Emerging research on PYY analogs and ghrelin antagonists further expands the therapeutic landscape. However, challenges remain in optimizing delivery methods, ensuring long-term efficacy, and mitigating potential side effects.
Gut hormone-based therapies represent a paradigm shift in the management of metabolic disorders. By harnessing the intricate signaling networks of the gut-brain axis, these innovative approaches offer the potential for more effective and targeted interventions in obesity and type 2 diabetes, paving the way for personalized treatment strategies in metabolic medicine.
Keywords: Gut-brain axis, Incretin mimetics, Metabolic syndrome, GLP-1/GIP co-agonists, Enteroendocrine signaling
Type of Study: Research |
Subject:
Special
Received: 2025/01/3 | Accepted: 2025/04/20 | Published: 2025/05/31
Received: 2025/01/3 | Accepted: 2025/04/20 | Published: 2025/05/31
References
1. Alemany M. The metabolic syndrome, a human disease. International journal of molecular sciences. 2024;25(4):2251. [DOI:10.3390/ijms25042251]
2. Khatun MM, Bhuia MS, Chowdhury R, Sheikh S, Ajmee A, Mollah F, et al. Potential utilization of ferulic acid and its derivatives in the management of metabolic diseases and disorders: An insight into mechanisms. Cellular Signalling. 2024;121:111291. [DOI:10.1016/j.cellsig.2024.111291]
3. Zakynthinos GE, Tsolaki V, Oikonomou E, Vavouranakis M, Siasos G, Zakynthinos E. Metabolic syndrome and atrial fibrillation: different entities or combined disorders. Journal of Personalized Medicine. 2023;13(9):1323. [DOI:10.3390/jpm13091323]
4. Iafusco D, Franceschi R, Maguolo A, Guercio Nuzio S, Crinò A, Delvecchio M, et al. From metabolic syndrome to type 2 diabetes in youth. Children. 2023;10(3):516. [DOI:10.3390/children10030516]
5. Sobieska K, Buczyńska A, Krętowski AJ, Popławska-Kita A. Iron homeostasis and insulin sensitivity: unraveling the complex interactions. Reviews in Endocrine and Metabolic Disorders. 2024;25(5):925-39. [DOI:10.1007/s11154-024-09908-7]
6. Zhang Y, Gu Z, Xu Y, He M, Gerber BS, Wang Z, et al. Global scientific trends in healthy aging in the early 21st century: A data-driven scientometric and visualized analysis. Heliyon. 2024;10(1): e23405 [DOI:10.1016/j.heliyon.2023.e23405]
7. Addissouky TA, Sayed IE, Ali MM, Wang Y, Baz AE, Khalil AA, et al. Latest advances in hepatocellular carcinoma management and prevention through advanced technologies. Egyptian Liver Journal. 2024;14(1):2. [DOI:10.1186/s43066-023-00306-3]
8. Addissouky TA, Ali MM, El Sayed IE, Wang Y, Khalil AA. Translational insights into molecular mechanisms of chemical hepatocarcinogenesis for improved human risk assessment. Advances in Clinical Toxicology. 2024;9(1):294. [DOI:10.23880/act-16000294]
9. Addissouky TA, Ali MM, El Sayed IE, Wang Y, El Baz A, Elarabany N, et al. Preclinical promise and clinical challenges for innovative therapies targeting liver fibrogenesis. Archives of Gastroenterology Research. 2023;4(1):14-23. [DOI:10.33696/Gastroenterology.4.044]
10. Addissouky TA. Transforming screening, risk stratification, and treatment optimization in chronic liver disease through data science and translational innovation. The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy. 2024;25(1):53-62. [DOI:10.24871/251202453-62]
11. Addissouky TA, El Sayed IE, Ali MM, Alubiady MH, Wang Y. Schisandra chinensis in liver disease: exploring the mechanisms and therapeutic promise of an ancient Chinese botanical. Archives of pharmacology and therapeutics. 2024;6(1):27-33. [DOI:10.33696/Pharmacol.6.052]
12. Lonardo A. The heterogeneity of metabolic syndrome presentation and challenges this causes in its pharmacological management: a narrative review focusing on principal risk modifiers. Expert Review of Clinical Pharmacology. 2023;16(10):891-911. [DOI:10.1080/17512433.2023.2259306]
13. Li S, Liu M, Cao S, Liu B, Li D, Wang Z, Sun H, Cui Y, Shi Y. The mechanism of the gut-brain axis in regulating food intake. Nutrients. 2023;15(17):3728. [DOI:10.3390/nu15173728]
14. Lu S, Zhao Q, Guan Y, Sun Z, Li W, Guo S, et al. The communication mechanism of the gut-brain axis and its effect on central nervous system diseases: A systematic review. Biomedicine & Pharmacotherapy. 2024;178:117207. [DOI:10.1016/j.biopha.2024.117207]
15. Pan I, Issac PK, Rahman MM, Guru A, Arockiaraj J. Gut-brain axis a key player to control gut dysbiosis in neurological diseases. Molecular Neurobiology. 2024;61(12):9873-91. [DOI:10.1007/s12035-023-03691-3]
16. Roh E, Choi KM. Hormonal gut-brain signaling for the treatment of obesity. International journal of molecular sciences. 2023;24(4):3384. [DOI:10.3390/ijms24043384]
17. Bany Bakar R, Reimann F, Gribble FM. The intestine as an endocrine organ and the role of gut hormones in metabolic regulation. Nature reviews Gastroenterology & hepatology. 2023;20(12):784-96. [DOI:10.1038/s41575-023-00830-y]
18. Lad SU, Vyas GS, Mohd S, Mishra V, Wadhwa S, Singh S, et al. Recent advances in therapeutic interventions of polycystic ovarian syndrome. Obesity Medicine. 2024;48:100543. [DOI:10.1016/j.obmed.2024.100543]
19. Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduction and Targeted Therapy. 2024 ;9(1):234. [DOI:10.1038/s41392-024-01931-z]
20. Holst JJ. GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management. Nature Metabolism. 2024;6(10):1866-85. [DOI:10.1038/s42255-024-01113-9]
21. Nicze M, Dec A, Borówka M, Krzyżak D, Bołdys A, Bułdak Ł, et al. Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy. International Journal of Molecular Sciences. 2024;25(15):8202. [DOI:10.3390/ijms25158202]
22. Lafferty RA, Flatt PR, Irwin N. GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy. Expert opinion on pharmacotherapy. 2023;24(5):587-97. [DOI:10.1080/14656566.2023.2192865]
23. Mariam Z, Niazi SK. Glucagon‐like peptide agonists: a prospective review. Endocrinology, Diabetes & Metabolism. 2024;7(1):e462. [DOI:10.1002/edm2.462]
24. Addissouky T, Ali MM, El Sayed IE, Alubiady MH. Realizing the promise of artificial intelligence in hepatocellular carcinoma through opportunities and recommendations for responsible translation. Jurnal Online Informatika. 2024;9(1):70-9. [DOI:10.15575/join.v9i1.1297]
25. Addissouky TA, Ali MM, Sayed IE, Wang Y. Emerging advanced approaches for diagnosis and inhibition of liver fibrogenesis. The Egyptian Journal of Internal Medicine. 2024;36(1):19. [DOI:10.1186/s43162-024-00283-y]
26. Addissouky TA, El Sayed IE, Ali MM, Alubiady MH, Wang Y. Bending the curve through innovations to overcome persistent obstacles in HIV prevention and treatment. Journal of AIDS and HIV Treatment. 2024;6(1):44-53. [DOI:10.33696/AIDS.6.051]
27. Addissouky TA, El Sayed IE, Ali MM, Alubiady MH. Optical insights into fibrotic livers: Applications of near-infrared spectroscopy and machine learning. Archives of Gastroenterology Research. 2024;5(1):1-10. [DOI:10.33696/Gastroenterology.5.048]
28. Addissouky TA, El Sayed IE, Ali MM, Wang Y, El Baz A, Khalil AA, et al. Can vaccines stop cancer before it starts? Assessing the promise of prophylactic immunization against high-risk preneoplastic lesions. Journal of Cellular Immunology. 2023;5(4):127-40. [DOI:10.33696/immunology.5.178]
29. Drucker DJ, Holst JJ. The expanding incretin universe: from basic biology to clinical translation. Diabetologia. 2023;66(10):1765-79. [DOI:10.1007/s00125-023-05906-7]
30. Scheen, A. J. Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes. Annales D'Endocrinologie, 2023;84(2):316-21. [DOI:10.1016/j.ando.2022.12.423]
31. Nogueiras R, Nauck MA, Tschöp MH. Gut hormone co-agonists for the treatment of obesity: from bench to bedside. Nature Metabolism. 2023;5(6):933-44. [DOI:10.1038/s42255-023-00812-z]
32. Addissouky TA, El Sayed IE, Ali MM, Wang Y, El Baz A, Elarabany N, et al. Oxidative stress and inflammation: elucidating mechanisms of smoking-attributable pathology for therapeutic targeting. Bulletin of the National Research Centre. 2024;48(1):16. [DOI:10.1186/s42269-024-01174-6]
33. Addissouky TA. Emerging Therapeutics targeting cellular stress pathways to mitigate end-organ damage in type 1 diabetes. Avicenna Journal of Medical Biochemistry. 2024;12(1):39-46. [DOI:10.34172/ajmb.2527]
34. Addissouky TA, Ali MM, El Sayed IE, Wang Y. Type 1 diabetes mellitus: retrospect and prospect. Bulletin of the National Research Centre. 2024;48(1):42. [DOI:10.1186/s42269-024-01197-z]
35. Addissouky T, Ali M, El Sayed IE, Wang Y. Revolutionary innovations in diabetes research: from biomarkers to genomic medicine. Iranian journal of diabetes and obesity. 2023;15(4):228-42. [DOI:10.18502/ijdo.v15i4.14556]
36. Xiao Y, Jin L, Zhang C. From a hunger-regulating hormone to an antimicrobial peptide: gastrointestinal derived circulating endocrine hormone-peptide YY exerts exocrine antimicrobial effects against selective gut microbiota. Gut Microbes. 2024;16(1):2316927. [DOI:10.1080/19490976.2024.2316927]
37. Smith KR, Moran TH. Gastrointestinal peptides in eating-related disorders. Physiology & behavior. 2021;238:113456. [DOI:10.1016/j.physbeh.2021.113456]
38. Nunez‐Salces M, Li H, Feinle‐Bisset C, Young RL, Page AJ. The regulation of gastric ghrelin secretion. Acta Physiologica. 2021;231(3):e13588. [DOI:10.1111/apha.13588]
39. Akalu Y, Molla MD, Dessie G, Ayelign B. Physiological effect of ghrelin on body systems. International journal of endocrinology. 2020;2020(1):1385138. [DOI:10.1155/2020/1385138]
40. Addissouky TA. Precision medicine for personalized cholecystitis care: integrating molecular diagnostics and biotherapeutics. Bulletin of the National Research Centre. 2024;48(1):89. [DOI:10.1186/s42269-024-01244-9]
41. Addissouky TA, Ali MM, El Sayed IE, Wang Y. Recent advances in diagnosing and treating helicobacter pylori through botanical extracts and advanced technologies. Archives of Pharmacology and Therapeutics. 2023;5(1):53-66. [DOI:10.33696/Pharmacol.4.045]
42. Addissouky TA, Wang Y, El Sayed IE, Baz AE, Ali MM, Khalil AA. Recent trends in Helicobacter pylori management: harnessing the power of AI and other advanced approaches. Beni-Suef University Journal of Basic and Applied Sciences. 2023;12(1):80. [DOI:10.1186/s43088-023-00417-1]
43. Pei Z, Zhou D, Yan J, Wang S, Yang X, Pei Z. Design and characterization of novel oxyntomodulin derivatives with potent dual GLP-1/glucagon receptor activation and prolonged antidiabetic effects. Life Sciences. 2020;253:117651. [DOI:10.1016/j.lfs.2020.117651]
44. Zhihong Y, Chen W, Qianqian Z, Lidan S, Qiang Z, Jing H, et al. Emerging roles of oxyntomodulin-based glucagon-like peptide-1/glucagon co-agonist analogs in diabetes and obesity. Peptides. 2023;162:170955. [DOI:10.1016/j.peptides.2023.170955]
45. Zhang M, Zhu L, Wu G, Zhang H, Wang X, Qi X. The impacts and mechanisms of dietary proteins on glucose homeostasis and food intake: A pivotal role of gut hormones. Critical Reviews in Food Science and Nutrition. 2024;64(33):12744-58. [DOI:10.1080/10408398.2023.2256400]
46. Malik D, Narayanasamy N, Pratyusha VA, Thakur J, Sinha N. Digestion and assimilation of nutrients. InTextbook of nutritional biochemistry. Singapore: Springer Nature Singapore . 2023:79-111 [DOI:10.1007/978-981-19-4150-4_4]
47. Addissouky TA, El Sayed IE, Ali MM, Alubiady MH, Wang Y. Towards personalized care: Unraveling the genomic and molecular basis of sepsis-induced respiratory complications. Archives of Clinical Toxicology. 2024;6(1):4-15. [DOI:10.46439/toxicology.6.026]
48. Addissouky TA, Sayed IE, Ali MM, Wang Y. Emerging biomarkers for precision diagnosis and personalized treatment of cystic fibrosis. Journal of Rare Diseases. 2024;3(1):28. [DOI:10.1007/s44162-024-00052-z]
49. Alicic RZ, Neumiller JJ. Incretin therapies for patients with type 2 diabetes and chronic kidney disease. Journal of Clinical Medicine. 2023;13(1):201. [DOI:10.3390/jcm13010201]
50. Andreasen CR, Andersen A, Vilsbøll T. The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease. Diabetologia. 2023;66(10):1846-58. [DOI:10.1007/s00125-023-05966-9]
51. Camilleri M, Acosta A. Newer pharmacological interventions directed at gut hormones for obesity. British Journal of Pharmacology. 2024;181(8):1153-64. [DOI:10.1111/bph.16278]
52. Tschöp M, Nogueiras R, Ahrén B. Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy. Diabetologia. 2023;66(10):1796-808. [DOI:10.1007/s00125-023-05929-0]
53. Addissouky TA, El Sayed IE, Ali MM, Alubiady MH, Wang Y. Recent developments in the diagnosis, treatment, and management of cardiovascular diseases through artificial intelligence and other innovative approaches. Journal of Biomed Research. 2024;5(1):29-40. [DOI:10.46439/biomedres.5.041]
54. Addissouky TA, El Sayed IE, Ali MM, Wang Y, El Baz A, Elarabany N, et al. Shaping the future of cardiac wellness: exploring revolutionary approaches in disease management and prevention. Journal of Clinical Cardiology. 2024;5(1):6-29. [DOI:10.33696/cardiology.5.048]
55. Lyons SA, Beaudry JL. Synergistic combinations of gut-and pancreas-hormone-based therapies: advancements in treatments for metabolic diseases. Endocrinology. 2023;164(11):bqad153. [DOI:10.1210/endocr/bqad153]
56. Beloqui A. Gut hormone stimulation as a therapeutic approach in oral peptide delivery. Journal of Controlled Release. 2024;373:31-7. [DOI:10.1016/j.jconrel.2024.07.007]
57. Kukova L, Munir KM, Sayeed A, Davis SN. Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology. 2024;20(10):939-52. [DOI:10.1080/17425255.2024.2401589]
58. Kaplan JM, Zaman A, Abushamat LA. Curbing the Obesity Epidemic: Should GLP-1 Receptor Agonists Be the Standard of Care for Obesity?. Current Cardiology Reports. 2024;26(9):1011-9. [DOI:10.1007/s11886-024-02097-4]
59. Wardeh R, Iswadi TH, Alsharayri H, Rashid F, Alhashemi N, Bashier A. Dual GLP-1/GIP agonist tirzepatide for diabetes and obesity: a review of the evidence. Journal of Diabetes and Endocrine Practice. 2024;7(01):15-24. [DOI:10.1055/s-0043-1775966]
60. Addissouky TA, El Sayed IE, Ali MM, Alubiady MH, Wang Y. Transforming glomerulonephritis care through emerging diagnostics and therapeutics. Journal of Biomed Research. 2024;5(1):41-52. [DOI:10.46439/biomedres.5.043]
61. Addissouky TA, El Sayed IE, Ali MM, Alubiady MH, Wang Y. Precision medicine and immunotherapy advances transforming colorectal cancer treatment. Journal of Cancer Biology. 2024;5(2):38-43. [DOI:10.46439/cancerbiology.5.063]
62. Addissouky TA, El Sayed IE, Ali MM, Alubiady MH, Wang Y. Harnessing innovation for the future of breast cancer management. Clinical Research in Oncology. 2024;1(1):10-7. [DOI:10.46439/Oncology.1.004]
63. Ansari S, Khoo B, Tan T. Targeting the incretin system in obesity and type 2 diabetes mellitus. Nature Reviews Endocrinology. 2024;20(8):447-59. [DOI:10.1038/s41574-024-00979-9.https://doi.org/10.1038/s41574-024-00997-7]
64. Ali A, Flatt PR, Irwin N. Gut-Derived Peptide Hormone Analogues and Potential Treatment of Bone Disorders in Obesity and Diabetes Mellitus. Clinical Medicine Insights: Endocrinology and Diabetes. 2024:11795514241238059. [DOI:10.1177/11795514241238059]
65. Mengoli M, Conti G, Fabbrini M, Candela M, Brigidi P, Turroni S, et al. Microbiota-gut-brain axis and ketogenic diet: how close are we to tackling epilepsy?. Microbiome Research Reports. 2023;2(4):32. [DOI:10.20517/mrr.2023.24]
66. Leigh SJ, Lynch CM, Bird BR, Griffin BT, Cryan JF, Clarke G. Gut microbiota-drug interactions in cancer pharmacotherapies: implications for efficacy and adverse effects. Expert Opinion on Drug Metabolism & Toxicology. 2022;18(1):5-26. [DOI:10.1080/17425255.2022.2043849]
67. Addissouky TA, Wang Y, El Tantawy El Sayed I, Majeed MA, Khalil AA. Emerging technologies and advanced biomarkers for enhanced toxicity prediction and safety pharmacology. Advances in Clinical Toxicology. 2024;9(1):293. [DOI:10.23880/act-16000293]
68. Addissouky TA, Wang Y, El Tantawy El Sayed I, Majeed MA, Khalil AA. Transforming toxicity assessment through microphysiology, bioprinting, and computational modeling. Advances in Clinical Toxicology. 2024;9(1):295. [DOI:10.23880/act-16000295]
69. Mehrotra N, Kharbanda S, Singh H. Peptide-based combination nanoformulations for cancer therapy. Nanomedicine. 2020;15(22):2201-17. [DOI:10.2217/nnm-2020-0220]
70. Finan B, Parlee SD, Yang B. Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH. Molecular Metabolism. 2021;46:101153. [DOI:10.1016/j.molmet.2020.101153]
71. Addissouky TA, El Sayed IE, Ali MM. Regenerating damaged joints: the promise of tissue engineering and nanomedicine in lupus arthritis. J Clinical Orthopaedics and Trauma Care. 2024;6(2):2694-0248.
72. Addissouky TA, El Sayed IE, Ali MM. Conservative and emerging rehabilitative approaches for knee osteoarthritis management. J Clinical Orthopaedics and Trauma Care. 2024;6(2):2694-0248.
73. Xu L, Yuan Y, Che Z, Tan X, Wu B, Wang C, Xu C, Xiao J. The hepatoprotective and hepatotoxic roles of sex and sex-related hormones. Frontiers in Immunology. 2022;13:939631. [DOI:10.3389/fimmu.2022.939631]
74. Firman C, Batterham RL. A new era in gut hormone-based pharmacotherapy for people with obesity. Proceedings of the Nutrition Society. 2022;81(3):217-26. [DOI:10.1017/S0029665122002695]
75. Olanrewaju OA, Sheeba F, Kumar A, Ahmad S, Blank N, Kumari R, et al. Novel therapies in diabetes: a comprehensive narrative review of GLP-1 receptor agonists, SGLT2 inhibitors, and beyond. Cureus. 2023;15(12):e51151. [DOI:10.7759/cureus.51151]
76. Patel D, Smith A. Patient initiation and maintenance of GLP-1 RAs for treatment of obesity. Expert Review of Clinical Pharmacology. 2021;14(10):1193-204. [DOI:10.1080/17512433.2021.1947796]
77. Wal P, Aziz N, Prajapati H, Soni S, Wal A. Current Landscape of Various Techniques and Methods of Gene Therapy through CRISPR Cas9 along with its Pharmacological and Interventional Therapies in the Treatment of Type 2 Diabetes Mellitus. Current Diabetes Reviews. 2024;20(6):110-27. [DOI:10.2174/0115733998263079231011073803]
78. Meng H, Nan M, Li Y, Ding Y, Yin Y, Zhang M. Application of CRISPR-Cas9 gene editing technology in basic research, diagnosis and treatment of colon cancer. Frontiers in Endocrinology. 2023;14:1148412. [DOI:10.3389/fendo.2023.1148412]
79. Addissouky TA, Wang Y, Megahed FA, El Agroudy AE, El Sayed IE, El-Torgoman AM. Novel biomarkers assist in detection of liver fibrosis in HCV patients. Egyptian Liver Journal. 2021;11:1-5. [DOI:10.1186/s43066-021-00156-x]
80. Addissouky TA, El Agroudy AE, El-Torgoman AM, El Sayed IE, Ibrahim EM. Efficiency of alternative markers to assess liver fibrosis levels in viral hepatitis B patients. Biomedical Research. 2019;30(2):1-6. [DOI:10.35841/biomedicalresearch.30-19-107]
81. Gigliotti G, Joshi R, Khalid A, Widmer D, Boccellino M, Viggiano D. Epigenetics, Microbiome and Personalized Medicine: Focus on Kidney Disease. International Journal of Molecular Sciences. 2024;25(16):8592. [DOI:10.3390/ijms25168592]
82. Wang RC, Wang Z. Precision medicine: disease subtyping and tailored treatment. Cancers. 2023;15(15):3837. [DOI:10.3390/cancers15153837]
83. Addissouky TA, Ayman E. El-Agroudy, Abdel Moneim AK El-Torgoman , Ibrahim E. El-Sayed.Efficacy of biomarkers in detecting fibrosis levels of liver diseases. World Journal of Medical Sciences. 2019;16(1):11-8.
84. Addissouky T. Detecting liver fibrosis by recent reliable biomarkers in viral hepatitis patients. American Journal of Clinical Pathology. 2019;152(1):S85. [DOI:10.1093/ajcp/aqz117.000]
85. Ahmed Z, Mohamed K, Zeeshan S, Dong X. Artificial intelligence with multi-functional machine learning platform development for better healthcare and precision medicine. Database. 2020;2020:baaa010. [DOI:10.1093/database/baaa010]
86. Alowais SA, Alghamdi SS, Alsuhebany N, Alqahtani T, Alshaya AI, Almohareb SN, et al. Revolutionizing healthcare: the role of artificial intelligence in clinical practice. BMC medical education. 2023;23(1):689. [DOI:10.1186/s12909-023-04698-z]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
